# Fenretinide in Treating Patients With Solid Tumors

> **NCT00003250** · PHASE1 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 31 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** fenretinide

## Key facts

- **NCT ID:** NCT00003250
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2014-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003250, "Fenretinide in Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00003250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
